Ackman's fund takes a beating on Valeant pricing worries

Valeant's ($VRX) stock has been slipping on drug-pricing worries, and one-time deal partner and company enthusiast Bill Ackman has certainly taken note. His hedge fund, Pershing Square Holding, recorded a 12.5% loss last month, Reuters reports, with news that lawmakers are looking into Valeant price hikes on a pair of older meds spooking investors. More